Jason Troy Fitzgerald, MD | |
12750 St Francis Dr Ste 320, Crown Point, IN 46307-0264 | |
(219) 662-0077 | |
(219) 662-9496 |
Full Name | Jason Troy Fitzgerald |
---|---|
Gender | Male |
Speciality | Thoracic Surgery |
Experience | 25 Years |
Location | 12750 St Francis Dr Ste 320, Crown Point, Indiana |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1851372346 | NPI | - | NPPES |
201347360 | Medicaid | IN |
Facility Name | Location | Facility Type |
---|---|---|
Franciscan Home Care | Hammond, IN | Home health agency |
Franciscan Health Crown Point | Crown point, IN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Franciscan Physician Network | 3072790682 | 989 |
News Archive
Though 40 million concussions are recorded annually, no effective treatment exists for them or for many other brain-related illnesses.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Surgeons who perform procedures to remove head and neck cancers often work for six to eight hours on what is typically major, invasive surgery, which many times comes with facial disfigurement and debilitating side effects for the patient.
LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases.
› Verified 3 days ago
Entity Name | Franciscan Physician Network |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
Though 40 million concussions are recorded annually, no effective treatment exists for them or for many other brain-related illnesses.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Surgeons who perform procedures to remove head and neck cancers often work for six to eight hours on what is typically major, invasive surgery, which many times comes with facial disfigurement and debilitating side effects for the patient.
LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Jason Troy Fitzgerald, MD Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Jason Troy Fitzgerald, MD 12750 St Francis Dr Ste 320, Crown Point, IN 46307-0264 Ph: (219) 662-0077 |
News Archive
Though 40 million concussions are recorded annually, no effective treatment exists for them or for many other brain-related illnesses.
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.
Surgeons who perform procedures to remove head and neck cancers often work for six to eight hours on what is typically major, invasive surgery, which many times comes with facial disfigurement and debilitating side effects for the patient.
LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases.
› Verified 3 days ago